Trastuzumab deruxtecan in advanced breast cancer patients with brain metastases or leptomeningeal metastases
•Trastuzumab deruxtecan showed superior intracranial overall response rate (ORR) and median progression-free survival (mPFS) than controls in both stable and active brain metastases.•DEBBRAH, TUXEDO-1, and DESTINY-Breast 12 confirm durable intracranial activity in brain metastases with trastuzumab d...
Saved in:
Published in | Cancer pathogenesis and therapy |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Elsevier B.V
01.05.2025
|
Online Access | Get full text |
Cover
Loading…
Be the first to leave a comment!